South San Francisco
Tel: (650) 294-8583
About Mammoth Biosciences
Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.
A short narrated animation of the molecular biology of CRISPR diagnostics (45 seconds).
32 articles about Mammoth Biosciences
Mammoth Biosciences to Present at the 2023 Annual Meeting of the American Society of Gene and Cell Therapy
Mammoth Biosciences today announced Janice Chen, Ph.D., chief technology officer and co-founder of Mammoth, will present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles, CA, May 16 - 20, 2023.
Mammoth Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference
Mammoth Biosciences, Inc. today announced its participation in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Mammoth Biosciences Announces Appointment of Phil Tinmouth, Siang Chin to Key Leadership Roles
Mammoth Biosciences, Inc., a biotechnology company building the next generation of CRISPR products with a mission to cure and detect diseases, announced the appointment of Phil Tinmouth as Chief Business Officer and Siang Chin as General Counsel.
Mammoth Biosciences Named to Fast Company’s 2022 List of the Next Big Things in Tech
Mammoth Biosciences , Inc., a biotech company harnessing next-generation CRISPR technology to cure and detect disease, today announced that it has been named to Fast Company’s 2022 Next Big Things in Tech list, honoring the technology breakthroughs that promise to shape the future of their industries.
Mammoth Biosciences Named in BioSpace’s 2023 Best Places to Work
Mammoth Biosciences, Inc., a biotech company harnessing next-generation CRISPR technology to cure and detect disease, today announced its recognition as a BioSpace 2023 Best Place to Work in the small employer category, a testament to the company’s continuous commitment to its employees, culture, and mission.
Mammoth Biosciences Named as an “Endpoints 11” Most Promising Startup of 2022
Mammoth Biosciences , a biotech company harnessing next-generation CRISPR technology to detect and cure disease, has been chosen by Endpoints News Editor John Carroll as one of the most promising biotech startups for this year’s Endpoints 11 annual special report.
Today, scientist-founders are likely to remain in charge, shepherding the companies they founded to the next iteration. BioSpace spoke with one such founder, Mammoth Biosciences' Trevor Martin.
Mammoth Biosciences Announces Key Leadership Appointments
Mammoth Biosciences, a biotech company building the next generation of CRISPR products to cure and detect disease, today announced the appointment of Elaine Sun as Chief Operating Officer (COO) and Chief Financial Officer (CFO).
Mammoth Biosciences Receives FDA Emergency Use Authorization for First CRISPR-based High-Throughput COVID-19 Test
Mammoth Biosciences, Inc. , today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its DETECTR BOOST ® SARS-CoV-2 Reagent Kit, a first of its kind high-throughput solution that combines the power of CRISPR with laboratory automation for SARS-CoV-2 testing.
Bayer has transformed its pipeline by acquiring multiple cell and gene therapy companies, paving the way for life-saving and life-altering therapies for patients with different disease types.
Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology
Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies.
Bayer and Mammoth Biosciences forged a strategic collaboration potentially valued at more than $1 billion. The partnership grants Bayer access to Mammoth’s CRISPR technology to develop in vivo gene-editing therapies.
Mammoth Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
Mammoth Biosciences, a biotech company building the next generation of CRISPR products to cure and detect disease, today announced its participation in the upcoming 40th Annual J.P. Morgan Healthcare Conference.
The life sciences industry might just be filling a bit richer this week as two major venture capital firms announced the closing of new funds.
Mammoth Biosciences just announced a collaboration with Vertex to develop in vivo gene-editing therapeutics for patients with either of two serious, but not-yet-disclosed diseases.
Money on the Move: September 8 – 14
9/15/2021Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies.
Mammoth will use the funds to build and broaden its stable of next-generation CRISPR products to detect and cure various diseases.
Mammoth Biosciences Raises $195 Million to Build Next-Generation CRISPR Products in Therapeutics and Diagnostics
Mammoth Biosciences, the biotech company leveraging the diversity of life to build the next generation of CRISPR products to cure and detect disease, today announced it has secured $195 million in financing, joining the select ranks of “unicorn” startups with a valuation of more than $1 billion.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.
The collaboration, announced Wednesday, aims to make disposable, hand-held diagnostics that are as accurate as lab tests and as easy to use as home pregnancy kits.